Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Exercise Therapy Benefits Patients with Knee & Hip OA

Lara C. Pullen, PhD  |  July 18, 2019

A meta-analysis confirms prior research suggesting exercise therapy benefits patients with knee and hip osteoarthritis (OA). The study found greater improvements in pain, function, performance and quality of life in patients with milder, as opposed to more severe, OA…

ACR’s Delegation to the AMA: How We Can Continue to Advance Rheumatology

Gary Bryant, MD, FACR  |  July 17, 2019

The House of Delegates (HOD) is the policy-making body of the American Medical Association (AMA), and twice a year, representatives of all seated specialties, service societies and state medical associations review hundreds of resolutions to determine which will become AMA policies. Once those policies and priorities are determined or updated, we benefit from the AMA…

Step Therapy Legislation in the States: Navigating a Varied & Complex System

Joseph Cantrell, JD  |  July 17, 2019

As the practice of step therapy grows more pervasive throughout the insurance industry, the protocols become increasingly confusing to navigate. Steps vary from insurer to insurer based on plan type, and formulary differences are too often based on economic incentives rather than outcome-based medicine. Patients are often left hanging in the balance while physicians’ offices…

CMS 2018 MIPS Performance Feedback, Final Score & Targeted Review Now Available

From the College  |  July 17, 2019

Your 2018 MIPS performance feedback and final score from the CMS are now available on the Quality Payment Program website. To learn more about performance feedback, view the frequently asked questions document from the CMS. The payment adjustment you will receive in 2020 is based on your score for the 2018 performance year. If you…

White House Scraps Proposal to Lower U.S. Drug Prices

Caroline Humer  |  July 14, 2019

(Reuters)—The Trump administration on Thursday scrapped one of its most ambitious proposals for lowering prescription medicine prices, backing down from a policy that would have required health insurers to pass on billions of dollars in rebates they receive from drugmakers to Medicare patients. The decision represents a new setback to President Donald Trump’s efforts to…

Upadacitinib + Methotrexate & Other csDMARDs in RA Patients

Michele B. Kaufman, PharmD, BCGP  |  July 12, 2019

A post-hoc analysis showed upadacitinib is safe and effective for treating RA patients when used with methotrexate or non-methotrexate csDMARDs…

Adalimumab for JIA-Associated Uveitis: 5-Year Follow-up

Lara C. Pullen, PhD  |  July 10, 2019

A five-year study in patients with juvenile idiopathic arthritis-associated uveitis found drug-induced disease remission did not persist once adalimumab was stopped after long-term treatment.

Lupus Pregnancy Outcomes Improved Over the Past 2 Decades

Reuters Staff  |  July 9, 2019

NEW YORK (Reuters Health)—Pregnancy outcomes in women with systemic lupus erythematosus (SLE) have improved markedly over the past two decades, although pregnancy risks remain higher than in women without lupus, according to a trends analysis. “Thirty years ago, most women with SLE were advised to avoid pregnancy because of high risks for maternal and fetal…

U.S. Appeals Court to Take Up Constitutionality of Obamacare

Nate Raymond  |  July 9, 2019

NEW ORLEANS (Reuters)—The future of Obamacare could be at stake on Tuesday when a coalition of Democratic-led states and House of Representatives urge a federal appeals court to overturn a Texas judge’s ruling that the U.S. healthcare reform law is unconstitutional. Republicans have repeatedly tried to repeal Obamacare, or the Affordable Care Act (ACA), since…

Opioids Commonly Prescribed for Gout Attacks

Reuters Staff  |  July 9, 2019

NEW YORK (Reuters Health)—Nearly three in 10 patients seeking care at the emergency department (ED) for acute gout will be discharged with a prescription for opioids, new research shows. “Our study suggests a high use of prescription opioid in patients discharged from the ED with a diagnosis of gout, a condition that can be managed…

  • « Previous Page
  • 1
  • …
  • 254
  • 255
  • 256
  • 257
  • 258
  • …
  • 814
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences